Tryton Medical gets European O.K. on new stent
Durham, N.C. —
With a CE Mark in hand, Durham-based Tryton aims to begin a commercial launch of its Tryton Side Branch Short Stent. Tryton’s stents are designed to address bifurcation lesions, which occur when plaque has built up at the juncture of a main artery and a side branch. Tryton’s stent system support both the main artery and the side branch. The Tryton Short Stent is 3 mm shorter in the main branch zone than the standard Tryton Side Branch Stent.
Tryton said it would launch its new stent next week in Paris during EuroPCR 2013, the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
Tryton’s Side Branch Stent is still an investigational device in the United States. The company has completed enrollment in a clinical trial. Data is expected to be ready for presentation in the fall at TCT 2013, the annual meeting of Transcatheter Cardiovascular Therapeutics.
Please Log In to add a comment.
Best of TechWire Insider
- Star Trek gets real: Durham startup delivers interactive holograms
- Every tech company needs to join 'Global Government Surveillance Reform' movement
- Durham entrepreneurs find ally in Charlotte medtech incubator
- GoGown deal shows power, necessity of networking for startups
- New GSK oncology consortium targets combination therapies
- Fighting hospital infections: A Durham nurse's dream produces the GoGown
- From photos to out-of-this-world art: Raleigh firm's software transforms images
- LabCorp expands gene tests for cancer - but don't confuse these with 23andMe
- ChannelAdvisor: Mobile cuts deeply into PC share of online shopping
- Inside Appia's latest funding deal: Debt beats dilution